160 related articles for article (PubMed ID: 34749675)
21. Safety, Acceptability and Adherence of Dapivirine Vaginal Ring in a Microbicide Clinical Trial Conducted in Multiple Countries in Sub-Saharan Africa.
Nel A; Bekker LG; Bukusi E; Hellstrӧm E; Kotze P; Louw C; Martinson F; Masenga G; Montgomery E; Ndaba N; van der Straten A; van Niekerk N; Woodsong C
PLoS One; 2016; 11(3):e0147743. PubMed ID: 26963505
[TBL] [Abstract][Full Text] [Related]
22. Women's experience receiving drug feedback and adherence counseling in MTN-025/HOPE - an HIV Prevention open-label trial of the Dapivirine Vaginal Ring.
Katz AWK; Balán IC; Reddy K; Etima J; Weber K; Tauya T; Atujuna M; Scheckter R; Ngure K; Soto-Torres L; Mgodi N; Palanee-Phillips T; Baeten JM; van der Straten A
AIDS Behav; 2022 Nov; 26(11):3607-3619. PubMed ID: 35536519
[TBL] [Abstract][Full Text] [Related]
23. Assessing Per-Sex-Act HIV-1 Risk Reduction Among Women Using the Dapivirine Vaginal Ring.
Stalter RM; Dong TQ; Hendrix CW; Palanee-Phillips T; van der Straten A; Hillier SL; Kiweewa FM; Mgodi NM; Marzinke MA; Bekker LG; Soto-Torres L; Baeten JM; Brown ER;
J Infect Dis; 2024 Apr; 229(4):1158-1165. PubMed ID: 38099506
[TBL] [Abstract][Full Text] [Related]
24. Experiences with simultaneous use of contraception and the vaginal ring for HIV prevention in sub-Saharan Africa.
Leslie J; Kiweewa F; Palanee-Phillips T; Bunge K; Mhlanga F; Kamira B; Baeten J; Katz A; Hillier S; Montgomery E;
BMC Womens Health; 2021 Apr; 21(1):175. PubMed ID: 33892693
[TBL] [Abstract][Full Text] [Related]
25. Depression Among Pregnant and Breastfeeding Persons Participating in Two Randomized Trials of the Dapivirine Vaginal Ring and Oral Pre-Exposure Prophylaxis (PrEP) in Malawi, South Africa, Uganda, and Zimbabwe.
Stoner MCD; Mathebula F; Sedze N; Seyama L; Mohuba R; Fabiano Z; Etima J; Young A; Scheckter R; van der Straten A; Piper J; Noguchi L; Montgomery ET; Balán IC
AIDS Behav; 2024 Jul; 28(7):2264-2275. PubMed ID: 38526641
[TBL] [Abstract][Full Text] [Related]
26. Impact of Women's Home Environment on Use of the Dapivirine Vaginal Ring for HIV Prevention in Sub-Saharan Africa.
Gichane MW; Katz AWK; Ngure K; Scheckter R; Woeber K; Reddy K; Tauya T; Zimba C; Etima J; Mangxilana N; Palanee-Phillips T; van der Straten A;
AIDS Behav; 2021 Dec; 25(12):3847-3857. PubMed ID: 34009480
[TBL] [Abstract][Full Text] [Related]
27. Brief Report: Dapivirine Vaginal Ring Use Does Not Diminish the Effectiveness of Hormonal Contraception.
Balkus JE; Palanee-Phillips T; Reddy K; Siva S; Harkoo I; Nakabiito C; Kintu K; Nair G; Chappell C; Kiweewa FM; Kabwigu S; Naidoo L; Jeenarain N; Marzinke M; Soto-Torres L; Brown ER; Baeten JM
J Acquir Immune Defic Syndr; 2017 Oct; 76(2):e47-e51. PubMed ID: 28542081
[TBL] [Abstract][Full Text] [Related]
28. Pregnancy and Infant Outcomes Among Women Using the Dapivirine Vaginal Ring in Early Pregnancy.
Makanani B; Balkus JE; Jiao Y; Noguchi LM; Palanee-Phillips T; Mbilizi Y; Moodley J; Kintu K; Reddy K; Kabwigu S; Jeenariain N; Harkoo I; Mgodi N; Piper J; Rees H; Scheckter R; Beigi R; Baeten JM
J Acquir Immune Defic Syndr; 2018 Dec; 79(5):566-572. PubMed ID: 30383589
[TBL] [Abstract][Full Text] [Related]
29. Self-reported removal and expulsion of the dapivirine vaginal ring: qualitative reports from female ring users and their male partners in the Ring Study (IPM 027).
Milford C; Ramlal H; Mofokeng R; Rambally Greener L; Nel A; Smit J; Malherbe M
BMC Public Health; 2024 May; 24(1):1458. PubMed ID: 38822304
[TBL] [Abstract][Full Text] [Related]
30. Adolescent Girls and Young Women's Experiences with Disclosing Oral PrEP or Dapivirine Vaginal Ring Use: a Multi-Country Qualitative Analysis.
Young AM; Mancuso N; Atujuna M; Tenza S; Chitukuta M; Kemigisha D; Ngure K; van der Straten A; Garcia M; Szydlo D; Soto-Torres L; Roberts ST
AIDS Behav; 2023 Dec; 27(12):3941-3951. PubMed ID: 37392268
[TBL] [Abstract][Full Text] [Related]
31. Male Partner Opinions of the Dapivirine Vaginal Ring Used During an Open-Label Extension HIV Prevention Trial in KwaZulu-Natal, South Africa.
Morar NS; Mansoor LE; Naidoo K; Katz AWK; Garcia M; Duma C; Precious Myeni NB; Tshbalala T; Naidoo S; Montgomery ET
J Acquir Immune Defic Syndr; 2023 Feb; 92(2):127-133. PubMed ID: 36302179
[TBL] [Abstract][Full Text] [Related]
32. Clinical and Virologic Outcomes Following Initiation of Antiretroviral Therapy Among Seroconverters in the Microbicide Trials Network-020 Phase III Trial of the Dapivirine Vaginal Ring.
Riddler SA; Balkus JE; Parikh UM; Mellors JW; Akello C; Dadabhai S; Mhlanga F; Ramjee G; Mayo AJ; Livant E; Heaps AL; O'Rourke C; Baeten JM;
Clin Infect Dis; 2019 Jul; 69(3):523-529. PubMed ID: 30346511
[TBL] [Abstract][Full Text] [Related]
33. Acceptability and use of a dapivirine vaginal ring in a phase III trial.
Montgomery ET; van der Straten A; Chitukuta M; Reddy K; Woeber K; Atujuna M; Bekker LG; Etima J; Nakyanzi T; Mayo AJ; Katz A; Laborde N; Grossman CI; Soto-Torres L; Palanee-Phillips T; Baeten JM;
AIDS; 2017 May; 31(8):1159-1167. PubMed ID: 28441175
[TBL] [Abstract][Full Text] [Related]
34. First Impressions Matter: How Initial Worries Influence Adherence to the Dapivirine Vaginal Ring.
van der Straten A; Browne EN; Shapley-Quinn MK; Brown ER; Reddy K; Scheckter R; Soto-Torres L; Palanee-Phillips T; Baeten JM; Mensch B;
J Acquir Immune Defic Syndr; 2019 Jul; 81(3):304-310. PubMed ID: 30844995
[TBL] [Abstract][Full Text] [Related]
35. Evaluating the potential impact and cost-effectiveness of dapivirine vaginal ring pre-exposure prophylaxis for HIV prevention.
Reidy M; Gardiner E; Pretorius C; Glaubius R; Torjesen K; Kripke K
PLoS One; 2019; 14(6):e0218710. PubMed ID: 31242240
[TBL] [Abstract][Full Text] [Related]
36. Impact of the Dapivirine Vaginal Ring on Sexual Experiences and Intimate Partnerships of Women in an HIV Prevention Clinical Trial: Managing Ring Detection and Hot Sex.
Laborde ND; Pleasants E; Reddy K; Atujuna M; Nakyanzi T; Chitukuta M; Naidoo S; Palanee-Phillips T; Baeten JM; Montgomery ET;
AIDS Behav; 2018 Feb; 22(2):437-446. PubMed ID: 29151197
[TBL] [Abstract][Full Text] [Related]
37. Relationship Type and Use of the Vaginal Ring for HIV-1 Prevention in the MTN 020/ASPIRE Trial.
Pleasants E; Tauya T; Reddy K; Mirembe BG; Woeber K; Palanee-Phillips T; Zimba C; Atujuna M; Montgomery ET;
AIDS Behav; 2020 Mar; 24(3):866-880. PubMed ID: 31111297
[TBL] [Abstract][Full Text] [Related]
38. Will dapivirine redeem the promises of anti-HIV microbicides? Overview of product design and clinical testing.
das Neves J; Martins JP; Sarmento B
Adv Drug Deliv Rev; 2016 Aug; 103():20-32. PubMed ID: 26732684
[TBL] [Abstract][Full Text] [Related]
39. Phase 1 pharmacokinetics and safety study of extended duration dapivirine vaginal rings in the United States.
Liu AY; Dominguez Islas C; Gundacker H; Neradilek B; Hoesley C; van der Straten A; Hendrix CW; Beamer M; Jacobson CE; McClure T; Harrell T; Bunge K; Devlin B; Nuttall J; Spence P; Steytler J; Piper JM; Marzinke MA;
J Int AIDS Soc; 2021 Jun; 24(6):e25747. PubMed ID: 34118115
[TBL] [Abstract][Full Text] [Related]
40. HIV-1 drug resistance among individuals who seroconverted in the ASPIRE dapivirine ring trial.
Parikh UM; Penrose KJ; Heaps AL; Halvas EK; Goetz BJ; Gordon KC; Hardesty R; Sethi R; Schwarzmann W; Szydlo DW; Husnik MJ; Chandran U; Palanee-Phillips T; Baeten JM; Mellors JW;
J Int AIDS Soc; 2021 Nov; 24(11):e25833. PubMed ID: 34762770
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
